Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,535 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pyrimidine depletion enhances targeted and immune therapy combinations in acute myeloid leukemia.
Elgamal OA, Fobare S, Vibhute S, Mehmood A, Vroom DC, Johnson ML, Stearns B, Lerma JR, Truxall J, Stahl E, Carmichael B, Orwick SJ, Mims AS, Curran E, Santhanam R, Tridandapani S, Phelps MA, Xie Z, Coss CC, Baker SD, Patrick J, Ezzell JK, Rai J, Pan J, Rai SN, Stillwell C, Wunderlich M, Abdulrahim M, Goodwin TE, Hilinski G, Bennett CE, Hertlein E, Byrd JC. Elgamal OA, et al. Among authors: xie z. JCI Insight. 2024 Apr 22;9(8):e173646. doi: 10.1172/jci.insight.173646. JCI Insight. 2024. PMID: 38646934 Free PMC article.
PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia.
Goswami S, Mani R, Nunes J, Chiang CL, Zapolnik K, Hu E, Frissora F, Mo X, Walker LA, Yan P, Bundschuh R, Beaver L, Devine R, Tsai YT, Ventura A, Xie Z, Chen M, Lapalombella R, Walker A, Mims A, Larkin K, Grieselhuber N, Bennett C, Phelps M, Hertlein E, Behbehani G, Vasu S, Byrd JC, Muthusamy N. Goswami S, et al. Among authors: xie z. Blood. 2022 Mar 3;139(9):1340-1358. doi: 10.1182/blood.2020010344. Blood. 2022. PMID: 34788382 Free PMC article.
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia.
Klisovic RB, Blum W, Liu Z, Xie Z, Kefauver C, Huynh L, Zwiebel JA, Devine SM, Byrd JC, Grever MR, Chan KK, Marcucci G. Klisovic RB, et al. Among authors: xie z. Leuk Lymphoma. 2014 Jun;55(6):1332-6. doi: 10.3109/10428194.2013.838764. Epub 2013 Nov 1. Leuk Lymphoma. 2014. PMID: 24015841 Free PMC article. Clinical Trial.
ROR1 targeted immunoliposomal delivery of OSU-2S shows selective cytotoxicity in t(1;19)(q23;p13) translocated B-cell acute lymphoblastic leukemia.
Goswami S, Chiang CL, Zapolnik K, Nunes J, Ventura A, Mo X, Xie Z, Lee LJ, Baskar S, Rader C, Byrd JC, Phelps M, Bhatnagar B, Muthusamy N. Goswami S, et al. Among authors: xie z. Leuk Res. 2022 Jul;118:106872. doi: 10.1016/j.leukres.2022.106872. Epub 2022 May 24. Leuk Res. 2022. PMID: 35640397 Free PMC article. No abstract available.
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia.
Klisovic RB, Blum W, Wei X, Liu S, Liu Z, Xie Z, Vukosavljevic T, Kefauver C, Huynh L, Pang J, Zwiebel JA, Devine S, Byrd JC, Grever MR, Chan K, Marcucci G. Klisovic RB, et al. Among authors: xie z. Clin Cancer Res. 2008 Jun 15;14(12):3889-95. doi: 10.1158/1078-0432.CCR-08-0109. Clin Cancer Res. 2008. PMID: 18559610 Free PMC article. Clinical Trial.
The Neonatal Fc Receptor Is Elevated in Monocyte-Derived Immune Cells in Pancreatic Cancer.
Thomas J, Torok MA, Agrawal K, Pfau T, Vu TT, Lyberger J, Chang H, Castillo AMM, Chen M, Remaily B, Kim K, Xie Z, Dillhoff ME, Kulp SK, Behbehani GK, Cruz-Monserrate Z, Ganesan LP, Owen DH, Phelps MA, Coss CC, Mace TA. Thomas J, et al. Among authors: xie z. Int J Mol Sci. 2022 Jun 25;23(13):7066. doi: 10.3390/ijms23137066. Int J Mol Sci. 2022. PMID: 35806069 Free PMC article.
11,535 results
You have reached the last available page of results. Please see the User Guide for more information.